Maryland, 7 May 2024: Zydus Lifesciences recently received its second Form 483 reprimand from the FDA within the span of one month. In the second write-up, the regulatory agency flagged issues ranging from unqualified employees performing sample collections to improper evaluation......
View Details

Related News

• Fake degrees seized from pvt institute in Hisar (13-12-2024)

---

• Health ministry assign testing labs for surgical and medical examination gloves (13-12-2024)

---

• DCGI asks States to approve all applications for medicines and medical devices for rare diseases within three months (13-12-2024)

---

• Karnataka to restructure drugs control dept, strengthen procedures (13-12-2024)

---

• US FDA identifies cases of liver injury after treatment with Intercept's Ocaliva (obeticholic acid) (13-12-2024)

---

• Fake platelets sold for 15 thousand rupees in Prayagraj, CMO ordered an inquiry (12-12-2024)

---

• Cardiac drug sales signal increase in heart ailments (12-12-2024)

---

• Banned cough syrup worth Rs 15 lakh seized, driver arrested (12-12-2024)

---

• Sales in the respiratory market reached Rs 1,638 crore in November 2024 (12-12-2024)

---

• Kenya Govt Cautions Kenyans after Unregistered Cancer Drug Hits Market (12-12-2024)

---